ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1357

Systemic Lupus Erythematosus and Assisted Reproductive Technology: A Case Series and Systematic Literature Review

Erinn Coe1, Emily Petrinec1 and Omer Pamuk2, 1Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland, OH, 2Division of Rheumatology, Case Western Reserve University/University Hospitals, Cleveland, OH

Meeting: ACR Convergence 2023

Keywords: pregnancy, sex hormones, Systemic lupus erythematosus (SLE), Women's health

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1345–1364) Reproductive Issues in Rheumatic Disorders Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Systemic lupus erythematosus (SLE) is one of the most common autoimmune diseases in women of childbearing age and female sex hormones are known to play a role in the pathophysiology of SLE. Multiple studies have suggested impaired ovarian reserve in patients with even mild SLE. Women with SLE may also be advised to defer pregnancy until disease remission; however, the likelihood of conception decreases with advancing age and the use of potentially gonadotoxic immunomodulatory agents. For these reasons, assisted reproductive technology (ART) is an important consideration for women with SLE who desire pregnancy. Patients with SLE utilizing ART are theoretically at increased risk of hormone-associated disease flare or thrombosis. In this study, we aim to evaluate outcomes in women with SLE who have utilized ART in our center. We also performed a systematic literature review regarding safety and efficacy of ART in women with SLE.

Methods: A retrospective chart review was performed at a large tertiary care center. Patients with a diagnosis of SLE whose records included mention of in-vitro fertilization (IVF) or ART between 2010-2023 were reviewed. All included patients had a diagnosis of SLE based on the modified 1997 ACR criteria. In addition, a literature search was performed using electronic databases including PubMed, Web of Science, and Cochrane Library. Studies that reported data for patients with SLE who utilized ART were included. Case reports were excluded. Data collected for both the case series and literature review included type of ART utilized and number of cycles performed, demographic data, obstetric history, autoantibody positivity, etiology of infertility, delivery mode, maternal outcomes including SLE disease activity, and fetal outcomes.

Results: Nine patients were included in the case series and 6 studies in the literature review. Amongst patients included in the case series, ART was performed in 7 patients with SLE and SLE developed after the use of ART in 2 patients. Table 1 summarizes the main clinical features of patients. A total of 25 ART stimulation attempts resulted in 10 intrauterine (IU) pregnancies (40%). Of these, 8 resulted in live births. Two patients had SLE flare while receiving hormonal therapy. Our literature review revealed 256 relevant articles. The full text of 25 articles was reviewed resulting in 6 eligible studies. Between these studies and our case series, 283 SLE patients were reviewed. A total of 610 ART cycles were analyzed. These ART cycles resulted in 148 IU pregnancies and clinical pregnancy rate was 24.3%. Live birth occurred in 133 cases (89.9%). Table 2 summarizes clinical features and major outcomes in the literature.

Conclusion: The rate of SLE flare in patients utilizing ART appears to be like that of SLE patients not receiving hormonal therapy. The success rate of ART in women with SLE is similar to that of the general population. This case series and review of the current literature supports the use of ART in patients with SLE who desire pregnancy.

Supporting image 1

Table 1. Clinical features of SLE patients.

Supporting image 2

Table 2. Summary of SLE patients who utilized ART in the literature.


Disclosures: E. Coe: None; E. Petrinec: None; O. Pamuk: None.

To cite this abstract in AMA style:

Coe E, Petrinec E, Pamuk O. Systemic Lupus Erythematosus and Assisted Reproductive Technology: A Case Series and Systematic Literature Review [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/systemic-lupus-erythematosus-and-assisted-reproductive-technology-a-case-series-and-systematic-literature-review/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/systemic-lupus-erythematosus-and-assisted-reproductive-technology-a-case-series-and-systematic-literature-review/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology